EuBiologics announced on November 13 that its V Plant in Chuncheon has obtained the Good Manufacturing Practice (GMP) certification from Russia’s Ministry of Industry and Trade. The certification complies with the standards set by the Eurasian Economic Union (EAEU) for pharmaceutical manufacturing and quality control.

The EAEU GMP certification simultaneously validates compliance with GMP standards across all five EAEU member countries — Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan. EuBiologics views this certification as a reaffirmation of its competitiveness in global vaccine manufacturing and quality management.

The EAEU region, with a combined population exceeding 180 million, is seen as a high-potential market due to its expected economic growth and the rapid expansion of its biopharmaceutical sector. By securing this certification, EuBiologics is now positioned to pursue a wide range of business opportunities in these countries, including the export of vaccines and other biopharmaceuticals, technology transfers, and contract development and manufacturing (CDMO) services.

A EuBiologics official stated, "This EAEU GMP certification signifies that our capabilities in vaccine manufacturing and quality management are recognized by the EAEU. It serves as a foundation for us to actively pursue the export of vaccines and adjuvants, as well as technological collaboration with member countries in the EAEU."

With this certification, EuBiologics aims to expand its footprint in the global vaccine market, leveraging the growing demand for high-quality biopharmaceuticals in the EAEU region.